HIV mutation literature information.


  HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
 PMID: 34762770       2021       Journal of the International AIDS Society
Table: G190A/E


  HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
 PMID: 33668946       2021       Pathogens (Basel, Switzerland)
Discussion: The minority mutations detected by NGS may have resulted from apolipoprotein B mRNA editing catalytic polypeptide (APOBEC)-mediated G-to-A hypermutation such as E138K, M184I and G190E in RT or spontaneous mutation during viral replication, or from PCR error, which was introduced by error-prone reverse transcriptase or PCR enzymes.


  Prevalence of HIV-1 Drug-Resistance Genotypes Among Unique Recombinant Forms from Yunnan Province, China in 2016-2017.
 PMID: 31914782       2020       AIDS research and human retroviruses
Abstract: Mutations such as M184V/I (35.4%) in NRTIs and K103N/R/S/T (25.4%), V179D/E/T/Y (18.9%), G190A/E/R/S (13.8%), and Y181C (9.2%) in NNRTIs were common among the HIV-1 URF strains relative to other mutations.


  Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
 PMID: 32180823       2020       Drugs in context
Introduction: Other single substitutions including G190E/S, V106A, Y188L, and M230L reduced DOR susceptibility >10-fold.


  Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
 PMID: 31976534       2020       The Journal of antimicrobial chemotherapy
Abstract: In comparison, the prevalence of the common NNRTI mutations V90I, K101E/P, K103N/S, E138A/G/K/Q/R/S, Y181C/I/V and G190A/E/S/Q were higher (8.9%, 7.9%, 28.6%, 12.6%, 14.2% and 8.9%, respectively).


  Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
 PMID: 32005262       2020       AIDS research and therapy
Abstract: While K103N (50.8%) and G190A/S/E/G (29.1%) were the most prevalent Non-Nucleoside Reverse Transcriptase Inhibitor (NNTRI) mutations.
Result: This was followed by G190A/S/E/G that occurred in 55 (30.2%) of the patients, P236L mutation occurred in 2 (1.1%) and L234I
Discussion: For NNRTI class, K103N mutation (53.8%) was indicated as the most prevalent mutation followed by G190A/S/E/G (30.2%) similar to a study done in sub-Saharan Africa that indicated K103N (38.7%) and G190A/S/E/G (21.8%) as the most prevalent.


  HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
 PMID: 32280691       2020       BioMed research international
Result: K103N (37.55%, 92/245) was the most frequent mutation, followed by G190A/E/K/Q/S/V (28.57%, 70/245), V179I/D/E/T (27.76%, 68/245), V106A/I/M (26.12%, 64/245), Y181C/V (18.78%, 46/245), K101E/H/P (14.69%, 36/245), Y188C/H/L (5.71%, 14/245),
Result: NNRTI-associated DRMs with extensively drug resistance such as G190A/E/K/Q/S/V, V179I/D/E/T, Y181C/V, and K101E/H/P reside in CRF55_01B and subtype B, C.


  The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017.
 PMID: 33347449       2020       PloS one
Abstract: 48 DRMs were identified from 43 samples, indicating a drug resistance prevalence of 12.1% (43/356), which include seven protease inhibitors (PIs) accessory DRMs (Q58E, L23I and I84M), two PIs major DRMs (M46I, M46L), seven nucleoside RT inhibitors DRMs (D67N, K70Q, K219R and M184L), and 32 non-nucleoside RT inhibitors DRMs (K103N, V179E, K238N, V179D,  PMID: 32925358       2020       Journal of acquired immune deficiency syndromes (1999)
Discussion: In this NNRTI-experienced population (N = 6893), intermediate-level (defined as detection of any RT V106A/M, Y188C/H, V108I, and K103N + P225H substitution) and high-level (defined as detection of any RT Y188L, M230L, G190E, V106A/M + F227L, and V106A/M + L234I substitutions) DOR resistance was seen in 12.7% and 6.1%, respectively, and the most common high-level DOR resistance-associated substitution was  PMID: 30640198       2019       The Pediatric infectious disease journal
Result: The most frequent mutations observed were K103N/S (48.0%), M184V (37.5%), G190A/S/E/Q/R (15.1%), and Y181C/G/V (13.8%) (Table 1).



Browser Board

 Co-occurred Entities




   Filtrator